CCL2 and neoplasm: Additionally, GEM treatment (20 mg/kg) stimulates the production of CCL2 in the tumor cells which recruits M-MDSC to the tumor niche, and CCL2 receptor antagonists, such as RS 504393, could block M-MDSC recruitment (95).